I型干扰素信号通路增强了KRAS突变肺瘤中的免疫检查点抑制
Fernando Fernández-García1, Ana Fernández-Rodríguez1, Coral Fustero-Torre2
1Experimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
概括
KRAS突变肺癌显示I型干扰素通路的早期损伤. 恢复这种途径可能会使这些瘤更容易对免疫治疗做出反应,而不考虑其他突变.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 肺癌是全球癌症死亡的主要原因之一.
- 克拉斯瘤基因驱动肺腺癌的很大一部分.
- 目前的KRAS抑制剂由于耐药性和瘤异质性而显示出有限的生存益处.
研究的目的:
- 识别KRAScoprotein表达引起的早期功能性改变.
- 确定这些早期变化是否在整个瘤进展过程中持续存在.
- 研究针对这些变化的潜力,以提高免疫疗法的疗效.
主要方法:
- 单细胞RNA测序的小鼠膜类型2细胞与瘤性Kras.
- 对具有KRAS突变和额外抑制突变 (p53,LKB1) 的小鼠和人类肺瘤的分析.
- 用I型干扰素 (IFN) -β和干扰素基因刺激器 (STING) 干预,以恢复IFN信号传输.
主要成果:
- 早期Kras激活会损害小鼠肺细胞中的I型干扰素通路.
- 这种I型IFN通路损伤在晚期KRAS突变瘤中保持,即使具有p53或LKB1突变.
- 恢复I型IFN信号将瘤从"冷"转化为"热",增强瘤的微环境.
结论:
- I型干扰素途径是KRAS驱动的肺瘤发生的关键早期事件.
- 增强I型IFN信号传递可以克服KRAS突变肺瘤中的免疫逃避.
- 准I型IFN通路有望改善各种KRAS突变肺癌的免疫治疗结果.
相关概念视频
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493


